MedPath

Plant Stanol Esters and Influenza Vaccination

Not Applicable
Completed
Conditions
Immune Response
Interventions
Biological: Influenza vaccine
Dietary Supplement: Plant stanol soft chews (2g per day)
Dietary Supplement: Plant stanol soft chews (3g per day)
Dietary Supplement: Control soft chews
Dietary Supplement: Plant stanol soft chews (4g per day)
Registration Number
NCT05706350
Lead Sponsor
Maastricht University Medical Center
Brief Summary

Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, recent studies have suggested that these compounds also beneficially influence the immune system, e.g. increasing vaccine-specific antibody titers. BMI and age have previously been negatively associated to vaccination responses. If plant stanols indeed have beneficial effects on the immune system, people with overweight or obesity and higher age might benefit from consuming plant stanols prior to receiving the influenza vaccination.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
137
Inclusion Criteria
  • Men and women
  • Aged 60 years or older (or 59, but turning 60 years during influenza season 2022/2023 (in line with RIVM guidelines))
  • BMI between 20 and 35 kg/m2
  • Currently not using products containing plant sterols or stanols (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
  • Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
  • Willing to keep the intake of fish oil and vitamin supplements constant
Exclusion Criteria
  • Already received influenza vaccination in 2022
  • Already had influenza in 2022
  • Allergy to an ingredient of the chews
  • Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
  • Excessive alcohol use (>20 consumptions per week)
  • Regular use of soft and/or hard drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Plant stanol group (2 grams per day)Influenza vaccineDietary Supplement: 4 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
Placebo groupInfluenza vaccineDietary Supplement: 6 placebo soft chews Soft chews that do not contain plant stanols
Plant stanol group (2 grams per day)Plant stanol soft chews (2g per day)Dietary Supplement: 4 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
Plant stanol group (3 grams per day)Plant stanol soft chews (3g per day)Dietary Supplement: 6 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
Plant stanol group (4 grams per day)Influenza vaccineDietary Supplement: 8 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
Placebo groupControl soft chewsDietary Supplement: 6 placebo soft chews Soft chews that do not contain plant stanols
Plant stanol group (3 grams per day)Influenza vaccineDietary Supplement: 6 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
Plant stanol group (4 grams per day)Plant stanol soft chews (4g per day)Dietary Supplement: 8 soft chews containing 0.5g plant stanols each (delivered as plant stanol esters) Soft chews containing 0.5g plant stanols each delivered as plant stanol esters
Primary Outcome Measures
NameTimeMethod
Vaccine specific IgM antibody titerMaximal change from T=0 (change T=0 to T=3 weeks or T=4 weeks)

The response to the Influenza vaccine will be measured by quantifying the specific IgM antibody titer

Secondary Outcome Measures
NameTimeMethod
Immune parameters (1)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Cytokine production by PBMCs after stimulation with antiCD3-antiCD28 antiCD28 antibodies using the TruCulture system

Leukocyte differential countDay - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Number of subgroups of leukocytes measured in EDTA plasma

Anthropometry (1)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Body weight

Anthropometry (5)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Waist-to-hip ratio

Leukocyte countDay - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Number of leukocytes measured in EDTA plasma

Fasted metabolism (2)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Serum lipid and lipoprotein profile

Fasted metabolism (3)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Plasma glucose

Anthropometry (4)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Hip circumference

DietDay - 1 (start study), T=4 weeks after vaccination (end of study)

Food frequency questionnaire is used to determine if the participants maintain their habitual diet and to determine if the participants do not consume plant stanols and/or sterols outside the intervention

Vaccine specific IgG antibody titerT=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

The response to the Influenza vaccine will be measured by quantifying the specific IgG antibody titer

Anthropometry (3)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Waist circumference

Immune parameters (2)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

hsCRP

Fasted metabolism (1)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Serum non-cholesterol sterols and stanols

Diary outcomes (2)Day - 1 (start study), T=4 weeks after vaccination (end of study)

Medication intake as assessed by the diary

Anthropometry (2)Day - 1 (start study)

Height

Liver elastographyDay - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Fibroscan

Liver fat contentDay - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Fibroscan

Diary outcomes (1)Day - 1 (start study), T=4 weeks after vaccination (end of study)

Adverse events as assessed by the diary

Trial Locations

Locations (1)

Maastricht University Medical Center

🇳🇱

Maastricht, Limburg, Netherlands

© Copyright 2025. All Rights Reserved by MedPath